Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (2192)	12/1/2000 9:07:21 PM
From: Miljenko Zuanic	Respond to of 52153

<<Point is an investor shouldn't give up on a biotech just because the first trial failed. If mgt is capable and the drug is sound, one can profit.>> If you were 3-5 year (patient) old SCIO investor, few months ago you would be very concerned. Mgt: If, If, .. , If, If,.. FDA was very (and it was very unusually) Natrecor supportive, so some credits are going to FDA too. Let me said clearly that I have nothing to complain about. Currently I hold SCIO, and traded several times in last three years gaining nice profit. However, I do not like this method. It opens space for mistake. Big mistake. I hope that SCIO mgt will continue to be more responsive and serious about company and business prospect. Miljenko [eom]